SCHEMBL22290298

SCHEMBL22290298

CNC(=O)CN(C)c1cc(Br)ccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ GAA P10253 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ EGFR P00533 3/20 0.38
▸ RIOK2 Q9BVS4 1/20 0.35
▸ MAT2A P31153 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ OPRM1 P35372 1/20 0.33
▸ OPRL1 P41146 1/20 0.33
▸ HCRTR1 O43613 1/20 0.33
▸ HCRTR2 O43614 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19513506 0.84 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1KDM4EGAALMNA
SCHEMBL22290646 0.82 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1KDM4EEGFRHCRTR1
SCHEMBL19501382 0.80 BCHE (0.43) SMN1; SMN2ALDH1A1KDM4EGAALMNA
SCHEMBL23705585 0.76 FPR2 (0.38) SMN1; SMN2ALDH1A1KDM4EEGFRHCRTR1
SCHEMBL23729975 0.74 GBA1 (0.39) SMN1; SMN2ALDH1A1KDM4ELMNAHTT
SCHEMBL21333424 0.73 POLB (0.53) SMN1; SMN2ALDH1A1KDM4EEGFRHCRTR1
SCHEMBL30731116 0.72 KDM4E (0.43) SMN1; SMN2ALDH1A1KDM4EGAAEGFR
SCHEMBL22291030 0.71 HRH3 (0.53) SMN1; SMN2ALDH1A1KDM4ELMNAEGFR
SCHEMBL3475222 0.71 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1KDM4ELMNAKMT2A
SCHEMBL17439216 0.71 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1KDM4ELMNAHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 — — EP disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 — — CN disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 — — US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 — — EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 — — CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SMN1; SMN2 40/4885ALDH1A1 2571/4885KDM4E 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback